In this issue:
SC spesolimab for generalised pustular psoriasis flares
Risankizumab vs apremilast for moderate plaque psoriasis
Persistence of second-line biologics in psoriasis
Tapinarof cream 1% for plaque psoriasis
Characteristics associated with multiple biologic failure
Guselkumab and risankizumab in PsA
Cardio-cerebrovascular disease and systemic anti-psoriatic therapy
Biologic treatments for nail psoriasis
Deucravacitinib vs biologics and non-biologics for plaque psoriasis
Herpes zoster in patients with psoriasis
Please login below to download this issue (PDF)